Summit’s pipeline consists of clinical, preclinical and discovery stage programmes and includes a number that have been developed from our innovative Seglin™ technology.
In addition, some of the programmes are partner funded, including the C. difficile programme, and these require no further investment from Summit but have the potential to deliver future value to the business.
Duchenne muscular dystrophy (DMD) is the most common form of the muscular dystrophies.
Read More
In recent years there has been increasing publicity surrounding the rise of so called hospital superbugs.
SMT C2100 is a Seglin being developed for the potential treatment of melanoma and other advanced cancers.
SMT 15000 is a Seglin that is being developed as a biodefence treatment for infectious diseases associated with bio-terrorism.
Summit have a diabetes programme focused on identifying novel compounds for use as drugs in both type I and type II diabetes treatment.
Our initial focus is directed towards the antiviral arena where new drugs to augment the current cocktails are still desperately required for combating Hepatitis C virus (‘HCV’).
Antivirals directed against herpes viruses and respiratory viruses are areas of increasing unmet need.
SMT D001 has successfully completed a Phase I study in healthy volunteers that demonstarated a 40% reduction in stimulated saliva production.
Seborrhoea (excess sebum production) is one of the main causes of acne and seborrhoeic dermatitis.
This is currently under construction.
Summit identified a novel series of molecules that show excellent levels of efficacy against both replicating and non-replicating TB.
